Tatva Chintan Pharma Chem · NSE: TATVA · BSE: 543321
Q4 FY25 results · Jan–Mar 2025
Tatva Chintan Pharma Chem reported revenue from operations of ₹107.86 crore (up 9.8% from Q4 FY24) and net profit of ₹1.03 crore (down 89.3% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 107.86 | 98.27 | +9.8% | 85.90 | +25.6% |
| Other income | 0.72 | 4.53 | −84.1% | 0.04 | 16x |
| Total income | 108.59 | 102.79 | +5.6% | 85.94 | +26.4% |
| Profit before tax | 2.03 | 13.69 | −85.2% | (0.23) | Turned profit |
| Net profit for the period | 1.03 | 9.61 | −89.3% | 0.14 | +646.4% |
| EPS, basic (₹) | 0.44 | 4.11 | −89.3% | 0.06 | +633.3% |
| Net margin (%) | 1.0 | 9.8 | 0.2 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 107.65 | 93.93 | +14.6% | 84.00 | +28.2% |
| Other income | 1.29 | 4.53 | −71.4% | 0.04 | 32x |
| Total income | 108.94 | 98.46 | +10.6% | 84.04 | +29.6% |
| Profit before tax | 1.55 | 12.28 | −87.3% | (1.65) | Turned profit |
| Net profit for the period | 1.09 | 8.25 | −86.7% | (1.17) | Turned profit |
| EPS, basic (₹) | 0.47 | 3.52 | −86.6% | (0.50) | Turned profit |
| Net margin (%) | 1.0 | 8.8 | -1.4 |
Consolidated
- Filed with BSE
- 02 May 2025, 20:12 IST
- Board meeting
- 02 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 02 May 2025, 20:12 IST
- Board meeting
- 02 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE